CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Emulate›
News
Emulate logo

Emulate

Emulate, Inc.: A Boston-based biotech firm innovating with Organs-on-Chips technology for precision medicine and product testing.

Boston, MA, US🇺🇸
Founded
2013
Loading
Overview
Analysis
Compare
Fundraising
Employees
News
Library

Latest News About Emulate

Emulate, a month-old UK AI startup founded by former Google DeepMind researchers, is in advanced talks to raise as much as $700M at a $3.7B valuation

Financial Times

Emulate, a month-old UK AI startup founded by former Google DeepMind researchers, is in advanced talks to raise as much as $700M at a $3.7B valuation

Sources: Emulate, a month-old UK AI startup founded by former Google DeepMind researchers, is in advanced talks to raise as much as $700M...

Sep 17, 2026

Emulate Launches Brain-Chip R1 to Advance Neurological Drug Development in Partnership with FUJIFILM Cellular Dynamics

Emulate, Inc.

Emulate Launches Brain-Chip R1 to Advance Neurological Drug Development in Partnership with FUJIFILM Cellular Dynamics

Emulate launched the Brain-Chip R1, a first-in-class isogenic model of the human neurovascular unit developed with FUJIFILM Cellular...

Nov 18, 2025

FDA's ISTAND Pilot Program accepts submission of first organ-on-a-chip technology designed to predict human drug-induced liver injury

U.S. Food and Drug Administration

FDA's ISTAND Pilot Program accepts submission of first organ-on-a-chip technology designed to predict human drug-induced liver injury

The FDA accepted the first letter of intent into its ISTAND Pilot Program for an organ-on-a-chip technology, a human Liver-Chip drug...

Sep 24, 2024

Organ chip firm Emulate debuts second-generation culture module

Drug Discovery & Development

Organ chip firm Emulate debuts second-generation culture module

Emulate introduced the Zoë-CM2 culture module, a second-generation instrument that prolongs cell life within its organ chips and automates...

Jan 1, 2024

Emulate Inc. closes $82M Series E to fund expansion of organ-on-a-chip products

TechCrunch

Emulate Inc. closes $82M Series E to fund expansion of organ-on-a-chip products

Emulate closed an $82 million Series E round led by Northpond Ventures and Perceptive Advisors to expand its organ-on-a-chip product...

Sep 7, 2021

Emulate, Inc. and AstraZeneca Collaborate on Organs-on-Chips Technology

BioSpace

Emulate, Inc. and AstraZeneca Collaborate on Organs-on-Chips Technology

Emulate struck a deal with AstraZeneca's IMED Biotech Unit to embed its Organs-on-Chips technology within the IMED Drug Safety...

May 16, 2018